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ممارسات الوقاية احلالية من اجللطات الدموية الوريدية بعد التدخالت 
الكهروفيسيولوجية داخل األوعية الدموية يف اململكة املتحدة
دراسة استعادية
كري�شتوفر �شاوندر�شون، �شايل هيكمان، الني ويلكين�شون، مظفر الطيبجي
abstract: Objectives: This study aimed to evaluate the incidence of venous thromboembolism (VTE) cases 
at the Leeds General Infirmary, Leeds, UK, as well as to survey current VTE practices and preventative strategies 
at other UK-based electrophysiology (EP) centres. Methods: This retrospective study involved all patients who 
underwent EP studies at Leeds General Infirmary from January 2014 to December 2016. In addition, a telephone 
survey was conducted of 35 other UK-based EP centres. Results: Of 1,020 patients who underwent EP studies at 
Leeds General Infirmary, 0.3% developed a post-procedural VTE. In addition, 28 other EP centres were surveyed 
(response rate: 80%), of which 18% reported VTE cases in the last two years. There were wide variations in VTE 
prevention strategies and the use of post-procedural thromboprophylaxis. Conclusion: Despite the low incidence 
of VTE cases, many UK centres continue to experience this complication with no consensus on optimal preventative 
strategies. As current VTE guidelines do not recommend antithrombotics after EP studies, further research is needed.
Keywords: Venous Thromboembolism; Cardiac Electrophysiological Techniques; Catheter Ablation; Heparin; Post- 
operative Complications; Risk Assessment; United Kingdom.
امللخ�ص: الهدف: هدفت هذه الدرا�شة التجريبية اإىل تقييم حالت الن�شمام اخلرثي الوريدي يف م�شتو�شف ليدز العام، ليدز، اململكة املتحدة 
الدرا�شة  �شملت هذه  الطريقة:  املتحدة.  اململكة  الأخرى يف  املراكز  الوقائية يف  وال�شرتاتيجيات  احلالية  املمار�شات  لأ�شتبيان  وكذلك   ،
ديسمرب  اإىل   2014 يناير  العام من  الذين خ�شعوا لدرا�شات كهروفي�شيولوجية يف م�شتو�شف ليدز  الأ�شرتجاعية جميع املر�شى  التجريبية 
2016. وبالإ�شافة اإىل ذلك، مت اإجراء اأ�شتبيان عرب الهاتف لـ 35 مركز اآخر يف اململكة املتحدة لديهم امكانيات الك�شف الكهروفي�شيولوجية. 
النتائج: من بني 1,020 مري�شًا خ�شعوا لدرا�شات كهروفي�شيولوجية يف م�شتو�شف ليدز العام، حدث الن�شمام اخلرثي الوريدي يف 0.3%. 
منهم بعد الدرا�شة. بالإ�شافة اإىل ذلك، مت عمل ا�شتبيان ل 28 مركز اآخر )معدل ال�شتجابة: %80(، منها %18 ذكرت حدوث حالت الن�شمام 
اخلرثي الوريدي يف العامني املا�شيني. كانت هناك اختالفات وا�شعة يف ا�شرتاتيجيات الوقاية من الأن�شمام اخلرثي الوريدي وا�شتخدام 
م�شادات التخرث بعد الدرا�شة الكهروفي�شيولوجية. اخلال�صة: على الرغم من انخفا�ص حالت الإ�شابة بالن�شمام اخلرثي الوريدي، اإل اأن 
العديد من املراكز يف اململكة املتحدة ل تزال تعاين من حدوثه دون وجود توافق يف الآراء حول ال�شرتاتيجيات الوقائية املثلى. مبا اأن 
اإر�شادات الوقاية من الن�شمام اخلرثي الوريدي احلالية ل تو�شي مب�شادات التخرث ، فهناك حاجة ملزيد من الأبحاث يف هذا املجال.
الكلمات املفتاحية: الن�شمام اخلرثي الوريدي؛ تقنيات القلب الكهروفي�شيولوجية؛ ال�شتئ�شال با�شتخدام الق�شطرة؛ الهيبارين؛ م�شاعفات ما بعد اجلراحة؛ 
تقييم املخاطر؛ اململكة املتحدة.
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Electrophysiology (ep) studies and radio- frequency ablation (RFA) require the introd-uction of multiple catheters into the venous 
system.1,2 A typical procedure involves the placement 
of 4–5 sheaths into the femoral veins through which EP 
catheters are passed into the heart. If necessary, access 
to the left-sided cardiac chambers is achieved via a 
trans-septal puncture or by accessing the left ventr-
icle with a retrograde approach via the femoral artery. 
However, the period of immobility during and after the 
procedure—typically up to six hours—is a known 
thrombotic risk factor. The incidence of asymptomatic 
deep vein thrombosis (DVT) in this setting ranges from 
5–18%, although the clinical incidence is substantially 
lower (0.4–2%).1–4 
Venous thromboembolism (VTE) has potentially 
serious clinical and financial consequences; according 
to the National Institute for Health and Care Excellence 
(NICE), an estimated 25,000 patients die every year from 
preventable VTE in the UK.5–8 The NICE guidelines 
recommend that clinicians assess and stratify all indiv-
iduals admitted to hospital in order to administer pro- 
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phylactic anticoagulants to those at risk of VTE.5 The 
European Heart Rhythm Association (EHRA) guidelines 
on the use of antithrombotics in EP procedures suggest 
the peri-procedural administration of therapeutic unfr- 
actionated heparin (UFH) to achieve an activated clotting 
time (ACT) of ≥300 seconds for left-sided procedures 
and consideration of its use in right-sided procedures.9 
However, they do not specifically recommend the use 
of oral anticoagulants or antiplatelets following EP 
procedures, except in cases of atrial fibrillation, flutter 
ablation or left-sided ventricular tachycardia ablation.9 
This study aimed to establish the incidence of 
post-procedural VTE among patients undergoing 
EP studies with or without RFA, excluding those taking 
therapeutic anticoagulants, at the Leeds General Infir- 
mary, Leeds, UK. In addition, other UK-based centres 
were surveyed to document whether they had exper-
ienced VTE in the last two years and current practices 
for VTE prevention.
Methods
This retrospective study took place at the Leeds 
General Infirmary between January 2014 and December 
2016. A review of the EP procedures database was perf- 
ormed to identify all patients with a documented compl- 
ication of DVT or a pulmonary embolism. The patients’ 
medical records were then checked to ensure that appr- 
opriate testing had been performed to confirm the 
diagnosis of VTE, such as ultrasound venography or 
computed tomography pulmonary angiography. The 
case notes of patients with confirmed VTE were then 
reviewed in terms of medical history, EP procedure 
and the administration of peri- and post-procedural 
antithrombotics. All patients who required pre- or post- 
procedural therapeutic anticoagulation measures—such 
as those with atrial fibrillation or flutter—were excluded 
from the study.
Subsequently, a telephone survey was conducted 
of EP consultants or registrars working at 35 National 
Health Service (NHS) Trust centres performing >100 
ablation procedures per year.10 The survey recorded 
whether the centres had experienced any cases of VTE 
complications in the last two years. Verbal instructions 
were given prior to the survey to ensure that patients 
requiring therapeutic anticoagulation were not included. 
In addition, data were collected on the centres’ 
current practices regarding the use of peri- and post-
procedural antithrombotics in both right-sided and 
left-sided EP procedures.
This study was approved as a service evaluation 
project by the Research & Innovation Department of 
the Leeds Teaching Hospital NHS Trust. All telephone 
Table 1: Sociodemographic, clinical and procedural charact-
eristics of post-procedural venous thrombosis cases at the 
Leeds General Infirmary, Leeds, UK (N = 3)
Characteristic Case 1 Case 2 Case 3
Sociodemographic
Gender Female Female Male
Age in years 64 68 81
Clinical
Presence of cardiac 
or respiratory 
comorbidities
None None IHD and COPD
Active cancer or 
cancer treatment
No No No









BMI in kg/m2 41 34 24
Procedural






EP study and 
attempted VT 
ablation
Duration in minutes 150 30 135
Access site RFV RFV RFV and 
artery with 
a retroaortic 
approach to the 
LV
Sheath sizes 2 × 5F 
2 × 7F
2 × 5F 
2 × 7F
1 × 4F 









Previous history of 

















No No 75 mg of aspirin 
daily
IHD = ischaemic heart disease; COPD = chronic obstructive pulmonary disease; 
VTE = venous thromboembolism; BMI = body mass index; EP = electrophysiol-
ogical; RFA = radiofrequency ablation; AVNRT = atrioventricular nodal re-entry 
tachycardia; VT = ventricular tachycardia; RFV = right femoral vein; LV = left 
ventricle.  *Prior to the activated clotting time being maintained at >300 seconds.
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survey participants gave informed verbal consent prior 
to participation in the study.  
Results
Out of 1,020 adult patients undergoing EP procedures 
at the Leeds General Infirmary during the study period, 
three patients (0.3%) had post-procedural pulmonary 
emboli. In addition, the third case had confirmed right- 
sided common femoral DVT. Two of the patients under- 
went right-sided procedures, while one patient underwent 
a left-sided procedure for attempted ventricular tachy- 
cardia ablation. The procedure times ranged from 30–150 
minutes. Two patients had high body mass indices. 
Case one was receiving oestrogen-containing therapy 
and case three had ischaemic heart disease along with 
chronic obstructive pulmonary disease. Two patients 
received a nominal dose of UFH at the start of the proc- 
edure, while the third received full therapeutic antico-
agulation; however, none of the patients received post-
procedural anticoagulation therapy. One patient took a 
daily dose of 75 mg of aspirin prior to the procedure, which 
was continued upon discharge [Table 1]. Following the 
VTE diagnosis, all patients diagnosed with pulmonary 
emboli received at least three months of oral therapeutic 
anticoagulants as recommended by current guidelines, 
with no further complications observed.11
Of the 35 UK-based centres performing >100 
ablation procedures per year, 28 centres participated 
in the survey (response rate: 80%). The majority (68%) 
had a formal process for reviewing EP complications. 
A quarter of the centres perceived VTE to be a serious 
complication following EP procedures, with 18% rep- 
orting cases of VTE complications occurring in the last 
two years. All of the centres confirmed that they adm- 
inistered therapeutic UFH (for an ACT of ≥300 seconds) 
during left-sided procedures. In contrast, only 7% used 
a nominal dose of UFH (3,000–5,000 U) during right- 
sided procedures. The majority of centres (61%) mobilised 
patients an average of 2–3 hours after their procedure, 
with other centres mobilising patients at 1–2 hours (11%), 
3–4 hours (25%) or >4 hours (3%). Most centres reported 
prescribing antiplatelet medications upon discharge to 
patients undergoing left-sided procedures, with very few 
centres prescribing these to patients undergoing right-
sided procedures (71% versus 18%, respectively). If anti- 
platelet medications were prescribed, the centres reported 
prescribing either aspirin or clopidogrel (dose range: 
75–300 mg) for a duration of 4–12 weeks [Figure 1]. None 
of the centres reported prescribing anticoagulants upon 
discharge. 
Discussion
At Leeds General Infirmary, 0.3% of patients undergoing 
EP procedures—excluding those on therapeutic anti- 
coagulants—were diagnosed with a VTE within 6–12 
weeks of the procedure. These findings are in accordance 
with those in the published literature.1–4 In addition, all 
three of the affected patients had additional VTE risk 
factors. Crucially, the survey identified a wide variation 
in VTE prevention strategies at UK-based EP centres, 
 
Figure 1: Flow chart showing the proportion of patients receiving antithrombotics/antiplatelets upon discharge and 
specific regimens according to UK-based electrophysiology centres (N = 28).
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particularly with regards to UFH use during right-sided 
EP procedures and the prescription of antithrombotic 
medications upon discharge. 
Peri-procedural UFH in left-sided EP procedures 
is a well-established therapy to reduce thromboembolic 
complications, particularly in atrial fibrillation, and is 
recommended in multiple guidelines.9,12 In the current 
study, all of the surveyed centres reported using peri-
procedural UFH during left-sided procedures. In 
contrast, the role of peri-procedural UFH in right-
sided procedures is unclear. Alizadeh et al. conducted 
a randomised clinical trial (RCT) in which 200 patients 
with right-sided supraventricular and ventricular tachy- 
arrhythmias undergoing EP studies with and without 
RFA were randomised to two groups; the first group was 
administered intra-procedural heparin (a 5,000-U bolus 
with subsequent ACT measurement), while the second 
received no anticoagulation measures.13 After 24 hours, 
duplex ultrasonography revealed no cases of symptom-
atic DVT in either group. However, there was a significant 
decrease in the rate of in situ thrombosis between the 
heparin and control groups (11% versus 28%; P = 0.04).13 
In another RCT, 27 patients undergoing EP studies 
were randomised to receive either a fixed dose of 5,000 U 
of low-molecular-weight heparin (LMWH) one hour 
before the procedure or no anticoagulation measures.14 
Duplex ultrasonography performed 24 hours, one week 
and one month after sheath removal demonstrated a 
significant reduction in asymptomatic venous thrombi 
cases in the LWMH group compared to the control group 
(18.1% versus 62.5%; P = 0.02). However, the trial had 
a very small sample size with no clinical incidences of 
DVT.14 Such studies provide a possible explanation for 
the low utilisation of peri-procedural anticoagulation 
therapy in right-sided procedures across the UK.13,14 In 
the current study, nominal doses of heparin did not 
prevent VTE complications occurring in two patients 
undergoing right-sided procedures.
Antiplatelet therapy is not indicated for VTE 
prophylaxis.5 Furthermore, the EHRA guidelines 
do not routinely recommend the use of oral antico-
agulants or post-procedural antiplatelet therapy for EP 
procedures, except for patients with atrial fibrillation, 
atrial flutter or left ventricular tachycardia.9 However, 
current clinical practices do not appear to reflect this; 
according to findings from the telephone survey, 71% 
of centres prescribed antiplatelet therapy after left-
sided procedures and 18% after right-sided procedures. 
A recent RCT of 176 patients who had undergone 
RFA—excluding atrial fibrillation ablation—compared 
the use of direct oral anticoagulants (10 mg of riva-
roxaban once a day) with aspirin (100 mg once a day) 
for three months after EP procedures.15 Duplex ultra-
sonography was performed 48–72 hours after the proc- 
edure, with no complete occlusive thrombus events. How- 
ever, rivaroxaban significantly decreased the incidence of 
nonocclusive thrombi compared to aspirin (5.8% versus 
16.7%; P = 0.023).15 The low event rate of symptomatic 
VTE in this population indicates that there is no cons- 
istent benefit of peri- or post-procedural antithrombotic 
therapy in VTE prevention. Therefore, further studies 
with larger samples are needed to substantiate recomm- 
endations for VTE prophylaxis after EP procedures. 
This retrospective study was subject to several 
limitations. Although patients were seen at least once 
after their procedure at the Leeds General Infirmary, 
some patients underwent longer-term follow-up at 
other district hospitals; thus, some VTE events may not 
have been reported. Additionally, patients with identified 
VTE complications also had other thrombotic risk 
factors, the influence of which was not evaluated in 
the present study. Furthermore, a small proportion of 
centres did not respond to the telephone questionnaire. 
Finally, the survey results were based on self-reported 
data from a single individual and thus may not be an 
accurate reflection of the wider experience or actual 
practices at the institutions.
Conclusion 
In this study, the post-procedural rate of VTE 
complications was 0.3% among patients undergoing 
EP studies with or without RFA at Leeds General Inf- 
irmary, excluding those who underwent atrial fibrillation 
ablation or who were taking oral anticoagulants. Unfort- 
unately, 18% of surveyed UK-based centres also reported 
having experienced this complication within the preceding 
two years, with current practices for the prevention of 
VTE differing between centres. Prophylactic measures 
for VTE prevention are hampered by a lack of data to 
aid decision-making. Therefore, larger-scale studies are 
required to adequately assess the risks and benefits of 
peri- and post-procedural thromboprophylaxis.
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